Alliance for Pandemic Preparedness

March 16, 2021

Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients

Category:

Topic:

Keywords (Tags):

  • Solid organ transplant recipients in the US were less likely to develop anti-SARS-CoV-2 antibody responses after receiving a single dose of either the Moderna or Pfizer-BioNTech vaccines. In a prospective convenience sample, only 17% (76 of 436) had detectable antibody responses at a median of 20 days after the first dose. Transplant recipients who were receiving immunosuppression therapy, older transplant recipients, and those vaccinated with the Pfizer-BioNTech vaccine (as compared to the Moderna vaccine) were less likely to develop detectable antibody responses.

Boyarsky et al. (Mar 15, 2021). Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients. JAMA. https://doi.org/10.1001/jama.2021.4385